Comparative Pharmacology
Head-to-head clinical analysis: LORYNA versus LYNORAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LORYNA versus LYNORAL.
LORYNA vs LYNORAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective mineralocorticoid receptor antagonist, blocking aldosterone binding to the mineralocorticoid receptor in epithelial and nonepithelial tissues.
LYNORAL is a progesterone receptor agonist that induces and maintains endometrial changes necessary for pregnancy support. It suppresses gonadotropin secretion, inhibiting ovulation, and alters cervical mucus consistency to impede sperm penetration.
5 mg orally once daily, with or without food. Maximum dose 10 mg once daily.
50 mg orally three times daily
None Documented
None Documented
Terminal elimination half-life is 18–24 hours in healthy adults; may be prolonged in severe hepatic impairment.
Terminal elimination half-life: 12–15 hours (11.2 ± 2.6 h in young adults; 14.8 ± 3.9 h in elderly), requiring once-daily dosing for steady-state within 4–7 days.
Primarily excreted via feces (80%) after biliary elimination; renal excretion accounts for approximately 10% as unchanged drug and metabolites.
Renal: ~50% as unchanged drug; ~20% as glucuronide conjugates. Biliary/fecal: ~30% (including enterohepatic recirculation).
Category C
Category C
Oral contraceptive
Oral contraceptive